SCHEDULE: Kynam Capital Updates Cogent Biosciences Stake to 4.33%
Schedule 13G Amendment
Kynam Capital Management and affiliates reported a 4.33% beneficial ownership stake in Cogent Biosciences, Inc. common stock as of December 31, 2025.
Summary
- Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang collectively reported beneficial ownership of 6,165,223 shares of Cogent Biosciences, Inc. common stock.
- This represents 4.33% of the issuer's class of securities.
- The filing is an Amendment No. 2 to a previous Schedule 13G statement.
- The event date requiring this filing was December 31, 2025.
- The reporting persons disclaim any intent to change or influence the control of Cogent Biosciences, Inc.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral. It is a routine amendment to a beneficial ownership report, indicating a continued, non-controlling stake below the 5% threshold, without specifying an increase or decrease from previous filings.
Positives
- NA
Negatives
- NA
Risks
- The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer, mitigating immediate control-related risks from this specific filing.
Future Outlook
This filing does not contain forward-looking statements or guidance from Cogent Biosciences, Inc. It solely reports beneficial ownership by Kynam Capital Management and its affiliates.
Industry Context
StockSavvy.ai notes that Schedule 13G filings are routine disclosures by passive investors holding significant stakes (typically 5% or more, or amendments to such holdings) in publicly traded companies. This filing indicates Kynam Capital Management's continued, albeit non-controlling, interest in Cogent Biosciences, a biotechnology company. Such filings provide transparency regarding institutional ownership, which can be a factor in investor sentiment.
Comparison to Industry Standards
- NA
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Ownership Certification | Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang certified that their securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Cogent Biosciences, Inc. | 02/17/2026 | This certification indicates a passive investment stance, suggesting no immediate intent by the reporting persons to engage in activist shareholder activities or seek board representation, which generally supports stable corporate governance. |
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake in the company, confirming Kynam Capital Management's continued interest in Cogent Biosciences, Inc.
Key Dates
| Date | Description |
|---|---|
| 12/31/2025 | Date of event which requires the filing of this statement, indicating the reporting period end for beneficial ownership. |
| 02/17/2026 | Signature date for Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang. |
Keywords
Cogent Biosciences, Kynam Capital Management, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Investment Management, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.